Résumé
Les modèles précliniques en cancérologie sont généralement utilisés pour tester des hypothèses générées grâce à la recherche fondamentale. Les expériences sur les modèles murins sont ainsi réalisées avant qu’un essai clinique ne soit entrepris chez l’homme. Bien que cette stratégie ait conduit à de nombreuses découvertes dans le domaine de l’immunothérapie, elle présente néanmoins plusieurs inconvénients. Pour cette raison, une approche bidirectionnelle itérative doit aujourd’hui être prise en considération. Dans un article récemment publié dans la revue Cancer Immunol Res, les défis de l’utilisation des modèles murins en immuno-oncologie ont été abordés. En même temps que les études précliniques participent au développement clinique, les données obtenues sur l’humain doivent également être utilisées pour générer de nouvelles hypothèses à tester sur les modèles animaux.
Abstract
Preclinical models in oncology are generally used to test hypotheses generated through basic science. Thus, experiments on murine models are carried out prior to conduct a clinical trial involving humans. Although this strategy has initially led to many discoveries in the field of immunotherapy, it has several disadvantages. Due to this reason, an iterative bidirectional approach should be considered. In a recent article published in Cancer Immunol Res, the challenges in the use of murine models in immunooncology were described in an interesting way. Indeed, at the same time than preclinical studies contribute to clinical development, human clinical data should also be used to generate new hypotheses to be tested in animal models.
Références
Tivol EA, Borriello F, Schweitzer AN, et al (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541–7
Waterhouse P, Penninger JM, Timms E, et al (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985–8
Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734–6
Curran MA, Montalvo W, Yagita H, Allison JP (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 107:4275–80
Begley CG, Ellis LM (2012) Drug development: raise standards for preclinical cancer research. Nature 483:531–3
Gould SE, Junttila MR, de Sauvage FJ (2015) Translational value of mouse models in oncology drug development. Nat Med 21:431–9
Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8:59–73
Flanagan SP (1966) “Nude”, a new hairless gene with pleiotropic effects in the mouse. Genet Res 8:295–309
Mellman I, Hubbard-Lucey VM, Tontonoz MJ, et al (2016) Derisking immunotherapy: report of a consensus workshop of the cancer immunotherapy consortium of the Cancer Research Institute. Cancer Immunol Res 4:279–88
Feig C, Jones JO, Kraman M, et al (2013) Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA 110:20212–7
Garin-Chesa P, Old LJ, Rettig WJ (1990) Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA 87:7235–9
Schiraldi M, Raucci A, Muñoz LM, et al (2012) HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med 209:551–63
Beatty GL, Chiorean EG, Fishman MP, et al (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331:1612–6
Vonderheide RH, Flaherty KT, Khalil M, et al (2007) Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25:876–83
Author information
Authors and Affiliations
Corresponding authors
About this article
Cite this article
Grazziotin-Soares, D., Lotz, JP. Le rôle des modèles murins en immuno-oncologie. Oncologie 19, 399–403 (2017). https://doi.org/10.1007/s10269-017-2731-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10269-017-2731-z